Vaxart, Inc.

Vaxart, Inc. is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of oral recombinant vaccines. The company's mission is to transform global health by pioneering oral pill vaccines that elicit both mucosal and systemic immunity against prevalent viral diseases. These innovative vaccines are designed to be administered as temperature-stable tablets, eliminating the need for refrigeration and needle injections, thereby enhancing accessibility and ease of use. Vaxart's headquarters are located in South San Francisco, California.

The company's pipeline focuses on developing prophylactic and therapeutic oral pill vaccines for a range of infectious diseases. Key candidates include vaccines targeting COVID-19, norovirus, seasonal influenza, and a therapeutic vaccine for human papillomavirus (HPV). Vaxart leverages its proprietary Vector-Adjuvant-Antigen Standardized Technology (VAAST) platform to develop these oral vaccines, which are intended to generate broad and durable immune responses.

Under the leadership of CEO Steven Lo, appointed in March 2024, Vaxart continues to advance its clinical programs. In January 2024, the company received a $9.27 million grant from the Biomedical Advanced Research and Development Authority (BARDA) to support a large-scale Phase 2b clinical trial for its COVID-19 vaccine candidate. A significant strategic development in late 2025 was a worldwide collaboration with Dynavax for its oral COVID-19 vaccine, which included an upfront payment and equity investment, extending Vaxart's cash runway into the second quarter of 2027. The company's market position is characterized by its innovative oral vaccine technology, which aims to disrupt the traditional vaccine market.